Epoprostenol (FLOLAN) is an intravenous medication used to treat primary pulmonary hypertension (PPH), a condition characterized by progressive increases in pulmonary artery pressure, leading to right ...
Dallas, TX - As new agents are developed for the treatment of primary pulmonary hypertension (PPH), long-term data are now becoming available on the first drug approved for this indication, ...
Myogen Receives Flolan Rights in U.S. and Will Launch Commercial Operations in Q2 '06 GlaxoSmithKline (LSE: GSK) (NYSE: GSK) and Myogen, Inc. (Nasdaq: MYOG) today announced a two-part collaboration in ...
A beeper-size device that pumps medicine through the skin has breathed new life into Loretta James. James, of Port Republic, Va., has life-threatening pulmonary hypertension, in which high blood ...
A first-of-its-kind oral drug has been shown to successfully treat primary pulmonary hypertension (PPH), according to the results of a multi-center trial led by UCSD School of Medicine pulmonary ...
By then, Flolan was in the third clinical trial stage. At the time, Flolan had to be administered to patients intravenously with a constant flow of the drug delivered to the heart. Dr. Rothblatt ...
Although it must conduct a Phase IV trial, United Therapeutics Corp. received FDA approval to market Remodulin for the treatment of pulmonary arterial hypertension in patients with New York Heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results